Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mizolastine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 19/20 | 0.84 |
| ▸ | CYP2D6 | P10635 | 17/20 | 0.84 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.71 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.70 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.70 |
| ▸ | HTR2B | P41595 | 1/20 | 0.70 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.70 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.70 |
| ▸ | HTR3A | P46098 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10337963 | 0.89 | HRH1 (0.67) | HRH1CYP2D6KCNH2CHRM1ADRA2A | |
| SCHEMBL9376971 | 0.89 | HRH1 (0.72) | HRH1CYP2D6KCNH2CHRM1ADRA2A | |
| SCHEMBL18388464 | 0.88 | HRH1 (0.78) | HRH1CYP2D6KCNH2CHRM1ADRA2A | |
| SCHEMBL5225966 | 0.85 | HRH1 (0.77) | HRH1CYP2D6KCNH2CHRM1ADRA2A | |
| SCHEMBL12930701 | 0.84 | HRH1 (0.71) | HRH1CYP2D6KCNH2CHRM1ADRA2A | |
| SCHEMBL12930707 | 0.83 | HRH1 (0.70) | HRH1CYP2D6KCNH2CHRM1ADRA2A | |
| SCHEMBL12930718 | 0.83 | HRH1 (0.70) | HRH1CYP2D6KCNH2CHRM1ADRA2A | |
| SCHEMBL20697482 | 0.83 | HRH1 (0.70) | HRH1CYP2D6KCNH2CHRM1ADRA2A | |
| SCHEMBL12930734 | 0.83 | HRH1 (0.70) | HRH1CYP2D6KCNH2CHRM1ADRA2A | |
| SCHEMBL12930742 | 0.83 | HRH1 (0.70) | HRH1CYP2D6KCNH2CHRM1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0958820-A1 | Use of an imidazol derivative for the manufacture of a medicament for treating auto-immunodiseases | SANOFI-SYNTHELABO (FR) | 1999-11-24 | — | — | EP | claimed |
| US-5891884-A | Use of an imidazole derivative for preventing and/or treating rhinitis | SYNTHELABO (FR) | 1999-04-06 | — | — | US | claimed |
| EP-0834315-A1 | Use of an imidazole derivative for the manufacture of a medicament for preventing and/or treating rhinitis | SYNTHELABO (FR) | 1998-04-08 | — | — | EP | claimed |
| EP-0217700-B1 | Benzimidazole derivatives, their preparation and their therapeutical use | SYNTHELABO (FR) | 1994-03-30 | — | — | EP | claimed |
| US-4912219-A | 2-[4-pyrimidin-2-yl amino)piperidin-1-yl]benzimidazole compound | SYNTHELABO (FR) | 1990-03-27 | — | — | US | claimed |
| JP-10101564-A | — | — | None | — | — | JP | disclosed |
| WO-2010151711-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | ALKERMES, INC. (US) | 2010-12-29 | — | — | WO | disclosed |
| EP-1007047-B1 | USE OF MIZOLASTINE FOR PREPARING A MEDICINE FOR TREATING INFLAMMATION | SANOFI AVENTIS (FR) | 2005-12-14 | — | — | EP | disclosed |
| US-20050202089-A1 | Sustained-release pharmaceutical formulations containing mizolastine | SANOFI-SYNTHELABO (FR) | 2005-09-15 | — | — | US | disclosed |
| EP-0906101-B1 | SLOW-RELEASE PHARMACEUTICAL FORMULATIONS CONTAINING MIZOLASTIN | SANOFI SYNTHELABO (FR) | 2002-06-19 | — | — | EP | disclosed |
| US-6165507-A | Slow-release pharmaceutical formulations containing mizolastine | SYNTHELABO (FR) | 2000-12-26 | — | — | US | disclosed |
| US-6140335-A | Use of mizolastine for treating inflammatory diseases associated with 5-lipoxygenase | SANOFI-SYNTHELABO (FR) | 2000-10-31 | — | — | US | disclosed |
| EP-1007047-A1 | USE OF MIZOLASTINE FOR PREPARING A MEDICINE FOR TREATING INFLAMMATION | SYNTHELABO (FR) | 2000-06-14 | — | — | EP | disclosed |
| EP-0958820-A1 | Use of an imidazol derivative for the manufacture of a medicament for treating auto-immunodiseases | SANOFI-SYNTHELABO (FR) | 1999-11-24 | — | — | EP | disclosed |
| US-5891884-A | Use of an imidazole derivative for preventing and/or treating rhinitis | SYNTHELABO (FR) | 1999-04-06 | — | — | US | disclosed |
| WO-1998047511-A1 | USE OF MIZOLASTINE FOR PREPARING A MEDICINE FOR TREATING INFLAMMATION | SANOFI-SYNTHELABO (FR) | 1998-10-29 | — | — | WO | disclosed |
| JP-H10101564-A | MEDICINE FOR PREVENTING AND/OR TREATING RHINITIS | MITSUBISHI CHEM CORP | 1998-04-21 | — | — | JP | disclosed |
| EP-0834315-A1 | Use of an imidazole derivative for the manufacture of a medicament for preventing and/or treating rhinitis | SYNTHELABO (FR) | 1998-04-08 | — | — | EP | disclosed |
| US-4912219-A | 2-[4-pyrimidin-2-yl amino)piperidin-1-yl]benzimidazole compound | SYNTHELABO (FR) | 1990-03-27 | — | — | US | disclosed |
| US-4820710-A | ANTIALLERGENS, ANTIHISTAMINES, ANTIINFLAMMATORY AGENTS | SYNTHELABO (FR) | 1989-04-11 | — | — | US | disclosed |